Highlights
1 patent
About
Antipsychotic Treatment for Schizophrenia and Mood Disorders
Mental-Heal by Abital is developing a novel oral antipsychotic drug, PGW-5, for the treatment of schizophrenia and bipolar disorder. PGW-5 is a neuroleptic, multi-target agent that is potentially effective for the treatment of schizophrenia symptoms and other cognitive deficits and mood disorders. The possible mechanisms underlying the differential effects of the drugs may involve the brain glutamate NMDA (N-Methyl-D-Aspartate receptor) system as well as neurotrophic factors and food intake regulating peptides. Early scientific work in animal models has shown that PGW-5 has anxiolytic and antidepressant activity and improves impaired social performance in PCP-treated mice.
Identity
| Name | Mental Heal |
|---|---|
| Slug | mental-heal |
| Type / kind | startup |
| Crunchbase ID | Mental Heal |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6LoNwLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2016 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Yigal Alon 98, Tel Aviv-Yafo, Israel |
Web & social
| https://www.linkedin.com/company/3481528 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatients
Business models
B2B
Tags
psychiatrypharmaceuticalsmental-healthschizophreniatreatments
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}